Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN (NYSE: QGEN) is highlighting its molecular testing portfolio as U.S. cyclosporiasis cases climb above 1,600 confirmed since May 2026, with another 7,000 potential cases under investigation. Health authorities are tracking multiple outbreaks of Cyclospora cayetanensis, a foodborne parasite not detectable by routine stool culture.
According to QIAGEN, its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 detects Cyclospora within about an hour as part of a 16-target gastrointestinal menu. For research and public health applications, QIAGEN offers a Cyclospora digital PCR assay for the QIAcuity system and the PulseNet-approved QIAseq FX DNA Library Prep Kit to support shotgun NGS workflows for identifying and characterizing foodborne pathogens.
QIAGEN (NYSE: QGEN) will release its Q2 2026 results on Wednesday, August 5, 2026, shortly after 22:05 Frankfurt / 21:05 London / 16:05 New York time. A related conference call will be held on Thursday, August 6, 2026, at 15:30 Frankfurt / 14:30 London / 09:30 New York time, with options to join by call-back registration, phone dial-in, or live audio webcast.
QIAGEN (NYSE: QGEN) has launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, expanding its QIAstat-Dx bloodstream infection testing menu. The new gram-negative panel detects 13 bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour.
Together with the recently introduced BCID GPF Plus AMR Panel, QIAstat-Dx now covers 33 pathogen targets and 28 AMR markers across gram-positive and gram-negative bacteria and fungi. The system is deployed in over 100 countries with more than 5,200 instruments installed as of end 2025.
QIAGEN (NYSE:QGEN) announced expansions to its QIAcuity digital PCR ecosystem to support wider adoption in research and biopharma. New offerings include planned gene expression assays for human, mouse and rat, a high-multiplex RNA kit, expanded Cell and Gene Therapy quality-control assays, enhanced QIAcuity Software 3.5 and Hamilton-based automation.
According to QIAGEN, QIAcuity has over 3,200 placements worldwide, 400+ multi-instrument customers and 1,100+ publications.
QIAGEN (NYSE:QGEN) announced two custom research-use-only QIAcuity digital PCR assays targeting Bundibugyo ebolavirus sequences linked to the current outbreak. These assays, designed for the QIAcuity system, focus on the virus’s NP and VP35 regions to support research, wastewater surveillance and environmental monitoring.
Initial in silico analysis showed no mismatches with reviewed outbreak sequences. The assays are make-to-order via QIAGEN’s custom workflow and complement in-stock QIAseq sequencing panels and sample preparation kits within the broader Sample to Insight portfolio.
QIAGEN (NYSE:QGEN) launched QIA Agent, an AI-powered digital assistant that supports experiment planning, product discovery and workflow guidance through a single conversational interface on www.qiagen.com.
The platform links natural-language queries to QIAGEN products, protocols, technical documentation and ordering tools, leveraging over 260,000 registered My QIAGEN users. It is globally available for research use only, not for diagnostic applications.
QIAGEN (NYSE:QGEN) is integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform into QIAGEN Digital Insights’ curated biomedical knowledge bases to support AI-driven drug discovery.
The collaboration applies graph-based AI to biomedical knowledge graphs to aid target identification, biomarker discovery and hypothesis generation, with initial pilot programs for select pharma and biotech partners.
QIAGEN (NYSE:QGEN) will propose several measures at its June 24, 2026 Annual General Meeting in Venlo. Key items include appointing co-founder Dr. Metin Colpan as Honorary Chairman, continued Supervisory Board renewal, a 40% dividend increase to $0.35 per share, and expanded share repurchase authorizations.
The company seeks approval for open-market buybacks of up to 10% of share capital plus a new $200 million synthetic share repurchase. CEO Thierry Bernard and CFO Roland Sackers are proposed for re-election to the Managing Board while a new CEO is expected in the second half of 2026.
QIAGEN (NYSE:QGEN) plans a fully automated QuantiFERON Sample to Insight workflow and an AI-enabled risk stratification tool, both targeted for late 2027. The workflow integrates QuantiFERON, Diasorin LIAISON systems and an Inpeco automation track. QIAGEN cites a ~75M annual latent TB test market growing ~4–5%/yr and reports >160M QuantiFERON tests performed.
QIAGEN (NYSE: QGEN) reported Q1 2026 net sales of $492 million (+2% reported, -1% CER) and diluted EPS of $0.33; adjusted diluted EPS was $0.54 CER, meeting the outlook. Adjusted operating margin was 27.4%. Sample technologies, QIAcuity and QDI grew; QuantiFERON fell on weaker immigration testing. Full‑year 2026 guidance reconfirmed at ~1–2% CER sales growth and adjusted diluted EPS of at least $2.43 CER.